but has the market / sales potential changed? I would say given eylea and lucentis have gone off patent (cheaper), it would make opt more easily to prescribe and afford for end users (ie. their health providers)
maybe opt could be used with avanstin off label too?
Ann: Trading Halt, page-118
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
-0.015(2.46%) |
Mkt cap ! $732.5M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 61.0¢ | 59.0¢ | $11.30M | 18.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 45916 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |